

| Table of Contents | Page No. |
|---|-----------------|
| List of Figures | xiii |
| List of Tables | xx |
| List of Abbreviations and Symbols | xxv |
| List of Materials, Equipments and Softwares | xxviii |
| Preface | xxxiii |
| 1. Introduction | 1 |
| 2. Literature review | 11 |
| 2.1 Oral drug delivery | 11 |
| 2.2 Physiology of the gastrointestinal tract | 12 |
| 2.3 Nanocarriers in oral drug delivery | 13 |
| 2.4 Transport of nanocarriers across the gastrointestinal barrier | 15 |
| 2.4.1. Paracellular transport | 15 |
| 2.4.2. Transcellular transport | 16 |
| 2.4.3. Carrier mediated transport | 17 |
| 2.4.4. Receptor mediated transport | 18 |
| 2.5 Polymeric nanoparticles | 19 |
| 2.6 Solid lipid nanoparticles | 25 |
| 2.7 Polymer-lipid hybrid nanoparticles | 29 |
| 2.8 Core-shell polymeric nanoparticles | 33 |
| 2.9 Drug specific literature review | 35 |
| 2.10 Research work done on cromolyn sodium | 38 |
| 2.11 Polymer specific review | 41 |
| 2.11.1. Poly-(D, L-lactide-co-glycolide) | 41 |
| 2.11.2. Poly-ε-caprolactone | 43 |
| 2.11.3. Chitosan | 44 |
| 2.12 Lipid specific review | 46 |
| 2.12.1. Soya lecithin | 46 |
| 2.12.2. Glyceryl monostearate | 48 |
| 3. Objective and plan of work | 51 |
| 3.1 Objective | 51 |
| 3.2 Study design | 51 |

| | |
|--|-----|
| 4. Analytical method development | 57 |
| 4.1 Experimental methods | 57 |
| 4.1.1 Analytical method development and validation for estimation of CS by UV-Visible spectroscopy | 57 |
| 4.1.2 Analytical method development and validation for estimation of CS by RP-HPLC in blood plasma | 61 |
| 4.2 Results and discussions | 64 |
| 4.2.1 Analytical method development and validation for estimation of CS by UV-Visible spectroscopy | 64 |
| 4.2.2 Analytical method development and validation for estimation of CS by RP-HPLC in blood plasma | 69 |
| 4.3 Summary | 73 |
| 5. CS encapsulated polymeric nanoparticles (CS-PNs) | 75 |
| 5.1 Experimental methods | 75 |
| 5.1.1 Pre-formulation studies | 75 |
| 5.1.2 Formulation of CS encapsulated polymeric nanoparticles | 77 |
| 5.1.3 Experimental design | 78 |
| 5.1.4 Characterizations of CS-PNs | 83 |
| 5.2 Results and discussions | 93 |
| 5.2.1 Pre-formulation studies | 93 |
| 5.2.2 Experimental design | 97 |
| 5.2.3 Characterizations of CS-PNs | 116 |
| 5.3 Summary | 137 |
| 6. CS encapsulated solid lipid nanoparticles (CS-SLNs) | 139 |
| 6.1 Experimental methods | 139 |
| 6.1.1 Pre-formulation studies | 139 |
| 6.1.2 Formulation of CS encapsulated solid lipid nanoparticles | 139 |
| 6.1.3 Experimental design | 140 |
| 6.1.4 Characterizations of CS-SLNs | 144 |
| 6.2 Results and discussions | 147 |
| 6.2.1 Pre-formulation studies | 147 |
| 6.2.2 Experimental design | 150 |

| | |
|---|-----|
| 6.2.3 Characterizations of CS-SLNs | 174 |
| 6.3 Summary | 195 |
| 7. CS encapsulated core-shell polymer-lipid hybrid nanoparticles (CS-PLHNs) | 197 |
| 7.1 Experimental methods | 197 |
| 7.1.1 Pre-formulation studies | 197 |
| 7.1.2 Formulation of CS encapsulated core-shell polymer-lipid hybrid nanoparticles | 197 |
| 7.1.3 Experimental design | 199 |
| 7.1.4 Characterizations of CS-PLHNs | 203 |
| 7.2 Results and discussions | 207 |
| 7.2.1 Pre-formulation studies | 207 |
| 7.2.2 Experimental design | 210 |
| 7.2.3 Characterizations of CS-PLHNs | 232 |
| 7.3 Summary | 256 |
| 8. CS encapsulated poly- ϵ -caprolactone-chitosan based core-shell polymeric nanoparticles (CS-PCCSNs) | 259 |
| 8.1 Experimental methods | 259 |
| 8.1.1 Pre-formulation studies | 259 |
| 8.1.2 Formulation of CS encapsulated poly- ϵ -caprolactone-chitosan based core-shell polymeric nanoparticles | 259 |
| 8.1.3 Experimental design | 260 |
| 8.1.4 Characterizations of CS-PCCSNs | 264 |
| 8.2 Results and discussions | 268 |
| 8.2.1 Pre-formulation studies | 268 |
| 8.2.2 Experimental design | 271 |
| 8.2.3 Characterizations of CS-PCCSNs | 292 |
| 8.3 Summary | 316 |
| 9. Comparative study of different nanocarriers as potential carrier for oral delivery of cromolyn sodium | 319 |
| 9.1 Encapsulation efficiency | 319 |
| 9.2 <i>In-vitro</i> drug release | 320 |
| 9.3 Accelerated and real time storage stability study | 322 |

| | |
|--|-----|
| 9.4 <i>Ex-vivo</i> intestinal permeation study | 323 |
| 9.5 <i>In-vivo</i> pharmacokinetic study | 326 |
| 9.6 Summary | 330 |
| 10. Conclusions | 331 |
| 11. References | 333 |
| List of papers communicated/published/accepted/presented | 355 |
| Reprint of published paper | |
| Personal profile of the candidate | |